Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852350 | 0.79 | EDNRB (0.33) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL831081 | 0.73 | MAOA (0.37) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL8011185 | 0.70 | ALDH1A1 (0.46) | MAOBMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL2230905 | 0.69 | MAPT (0.48) | ATMCYP2C9MAPTMEN1KMT2A | |
| SCHEMBL5338145 | 0.68 | MEN1 (0.35) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL7892212 | 0.68 | ALDH1A1 (0.41) | MAOAMAOBMAPTGRM2MEN1 | |
| SCHEMBL8655488 | 0.67 | MAOA (0.40) | MAOAMAOBATMHDAC3HDAC4 | |
| SCHEMBL599351 | 0.66 | S100A4 (0.40) | MAOAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL16012917 | 0.66 | MEN1 (0.40) | MAOAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL11052520 | 0.66 | POLB (0.40) | MAOAMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023010119-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| EP-3877514-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | In8bio, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-12 | — | — | US | disclosed |
| EP-3594343-B1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | INST CURIE (FR) | 2021-04-21 | — | — | EP | disclosed |
| WO-2021048235-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2305221-A1 | Dna damage repair inhibitors for treatment of cancer | Kudos Pharmaceuticals Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
| US-6514983-B1 | Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase | GUILFORD PHARMACEUTICALS INC. | 2003-02-04 | — | — | US | disclosed |
| US-6306889-B1 | FUSED HETEROCYCLIC DRUGS FOR CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | MAOA 2564/4885MAOB 2454/4885ATM 227/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | MAOA 3848/4885MAOB 2738/4885ATM 89/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | MAOA 4590/4885MAOB 4319/4885ATM 96/4885 |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | MAOA 3899/4885MAOB 2826/4885ATM 96/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | MAOA 3869/4885MAOB 2811/4885ATM 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.